# Superluminal Medicines raises USD 60 million in Series B financing

On 2026-09-03, according to Xiniu Data, Superluminal Medicines completed Series B financing, raising USD 60 million. Investors were lead investor BVF Partners, RA Capital Management, Perceptive Advisors, NVIDIA and others. The company is a provider of U.S. AI generation drugs services.



Canonical: https://uniquebase.ai/news/22da73b7-c7eb-4a01-b246-146e4f248acc
Stable identifier: 22da73b7-c7eb-4a01-b246-146e4f248acc
Snapshot captured: 2026-10-20T18:19:32.670Z
English updated: 2026-10-20T18:23:32.195Z

## Connected profiles

- [BVF Partners](/institutions/bvf-partners)
- [Catalio Capital Management](/institutions/catalio-capital-management)
- [Cooley](/institutions/cooley)
- [Deep Track Capital](/institutions/deep-track-capital)
- [Eli Lilly](/institutions/eli-lilly)
- [Gaingels](/institutions/gaingels)
- [Insight Partners](/institutions/insight-partners)
- [NVIDIA](/institutions/nvidia)
- [Perceptive Advisors](/institutions/perceptive-advisors)
- [RA Capital Management](/institutions/ra-capital-management)
- [Superluminal Medicines](/companies/superluminal-medicines)

## Sources

- No source links are available for this profile.